Xia Xiao-Feng, Xia Gui-Yang, Wu Yu-Zhuo, Xia Huan, Wang Ling-Yan, Shang Hong-Cai, Lin Sheng
Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing 100700, China.
Zhongguo Zhong Yao Za Zhi. 2022 Apr;47(7):1705-1729. doi: 10.19540/j.cnki.cjcmm.20220210.201.
The traditional Chinese medicine(TCM) contains very complex constituents. Besides the major constituents, there are a large number of unclear trace constituents with novel skeletons and potent bioactivities, which have been regarded as one of the important therapeutic substances and the great resources of innovative drugs derived from TCM. The present review highlighted that the development of the trace therapeutic substances of TCM is closely depends on the advanced technologies for their identification, isolation, structure elucidation, and bioactivity evaluation. Additionally, this paper reviewed the novel trace compounds derived from Chinese herbal medicines which have been published in Organic Letters during 2001-2021, and summarized the important licensed drugs originated from the trace therapeutic substances and the discovery and development of trace therapeutic substances of 8 kinds of Chinese herbal medicines. This review provides references for the research and development of TCM therapeutic substances and innovative drugs.
中药含有非常复杂的成分。除了主要成分外,还有大量结构新颖、生物活性强的不明微量成分,这些成分被视为中药重要的治疗物质之一和创新药物的巨大资源。本综述强调,中药微量治疗物质的发展紧密依赖于其鉴定、分离、结构解析和生物活性评价的先进技术。此外,本文综述了2001年至2021年期间发表在《有机快报》上的源自中药材的新型微量化合物,并总结了源自微量治疗物质的重要上市药物以及8种中药材微量治疗物质的发现与开发。本综述为中药治疗物质和创新药物的研发提供参考。